Literature DB >> 24778053

Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.

Tomonori Iida1, Yukio Nakabayashi, Norimitsu Okui, Hiroaki Shiba, Masahiko Otsuka, Katsuhiko Yanaga.   

Abstract

A 63-year-old woman was admitted to our Hospital for treatment of pancreatic head ductal carcinoma, and underwent pancreaticoduodedectomy (PD) in October 2007. At one month after surgery, she received systemic adjuvant chemotherapy using S-1 for three months. Because the serum carbohydrate antigen 19-9 (CA19-9) value was elevated at 23 months after surgery, the patient underwent systemic chemotherapy using gemcitabine. The serum CA19-9 decreased, but abdominal Computed Tomography (CT) revealed a hepatic metastasis in the ventrolateral segment of left hepatic lobe at 28 months after surgery. The chemotherapy was changed to oral S-1. At 35 months after surgery, abdominal CT revealed reduction of liver metastasis and that the serum CA19-9 was normalized, but chemotherapy had to be withdrawn because of severe myelosuppression. Because of her good general condition, the patient underwent partial hepatectomy for the liver metastasis. Histopathological examination demonstrated a complete response. Thirty six months after hepatectomy and 6 years after PD, the patient remains well without recurrence. We herein report a case of successful treatment for metachronous liver metastasis from pancreatic ductal carcinoma after PD by chemotherapy and hepatectomy and review the current literature.

Entities:  

Keywords:  Liver metastasis from pancreatic cancer; chemotherapy; gemcitabine; hepatectomy

Mesh:

Substances:

Year:  2014        PMID: 24778053

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Surgery for isolated liver metastases from pancreatic cancer.

Authors:  Nicola Zanini; Raffaele Lombardi; Michele Masetti; Marco Giordano; Giovanni Landolfo; Elio Jovine
Journal:  Updates Surg       Date:  2015-02-22

2.  Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI.

Authors:  Christos Nikolaou; Alexios Matikas; Maria Papavasilopoulou; Dimitris Mavroudis; Lampros Vamvakas
Journal:  Case Rep Oncol Med       Date:  2015-05-21

3.  Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

Authors:  Florian Gebauer; Alexander Ioannis Damanakis; Dirk Waldschmidt; Christiane Bruns; Felix Popp; Alexander Quaas; Fabian Kütting; Katrin Lutz; Swantje Held; Burkhard Deuß; Tobias Göser
Journal:  BMC Cancer       Date:  2021-11-18       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.